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Abstract
Few studies have investigated physiologic and cognitive effects of ‘‘long-term’’ electromagnetic field (EMF) exposure in
humans or animals. Our recent studies have provided initial insight into the long-term impact of adulthood EMF exposure
(GSM, pulsed/modulated, 918 MHz, 0.25–1.05 W/kg) by showing 6+ months of daily EMF treatment protects against or
reverses cognitive impairment in Alzheimer’s transgenic (Tg) mice, while even having cognitive benefit to normal mice.
Mechanistically, EMF-induced cognitive benefits involve suppression of brain b-amyloid (Ab) aggregation/deposition in Tg
mice and brain mitochondrial enhancement in both Tg and normal mice. The present study extends this work by showing
that daily EMF treatment given to very old (21–27 month) Tg mice over a 2-month period reverses their very advanced brain
Ab aggregation/deposition. These very old Tg mice and their normal littermates together showed an increase in general
memory function in the Y-maze task, although not in more complex tasks. Measurement of both body and brain
temperature at intervals during the 2-month EMF treatment, as well as in a separate group of Tg mice during a 12-day
treatment period, revealed no appreciable increases in brain temperature (and no/slight increases in body temperature)
during EMF ‘‘ON’’ periods. Thus, the neuropathologic/cognitive benefits of EMF treatment occur without brain
hyperthermia. Finally, regional cerebral blood flow in cerebral cortex was determined to be reduced in both Tg and
normal mice after 2 months of EMF treatment, most probably through cerebrovascular constriction induced by freed/
disaggregated Ab (Tg mice) and slight body hyperthermia during ‘‘ON’’ periods. These results demonstrate that long-term
EMF treatment can provide general cognitive benefit to very old Alzheimer’s Tg mice and normal mice, as well as reversal of
advanced Ab neuropathology in Tg mice without brain heating. Results further underscore the potential for EMF treatment
against AD.
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Introduction
Despite the best efforts of pharmaceutical industry and
academia, no new drugs against Alzheimer’s Disease (AD) have
been developed since 2003 [1]. Moreover, currently available
drugs (acetylcholinesterase inhibitors and/or N-metyle D-aspar-
tate (NMDA) antagonists) only treat/mask AD symptoms for
about one year, if at all - none of them directly slow or lessen AD
pathogenesis itself. In view of the universal failure of every major
drug trial to alter the course of AD, it is time to think outside the
‘‘pharmaceutical box’’ by considering non-pharmaceutical ap-
proaches that are safe, disease modifying, and can be expeditiously
explored to treat AD. We propose high frequency electromagnetic
field (EMF) treatment could be that approach, based on several
epidemiologic studies [2,3] and our recently completed EMF
studies in Alzheimer’s transgenic (Tg) mice [4,5].
In humans, high frequency EMF exposure/treatment studies
have essentially involved ‘‘cell phone level’’ EMF parameters
(pulsed, modulated and primarily GSM), in large part because of
initial concerns that high frequency EMF exposure may induce
health problems such as brain cancer [6,7]. However, the recent
13-nation INTERPHONE study [8], as well as analytic findings
from NIEHS [9] and numerous epidemiologic studies [10–12], all
collectively conclude that there is no consistent evidence that long-
term exposure of adults or children/adolescents to cell phone level
EMFs causes brain tumors, or very likely any other health
problems for that matter. In concert with these studies alleviating
safety issues related to high frequency EMF exposure, dozens of
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EEG, cerebral blood flow, and auditory processing) effects of cell
phone level EMF exposure. With rare exception [13,14], these
studies only involved brief (3–120 minute), single EMF exposure at
GMS, CW, or UMTS cell phone parameters given to normal
subjects. Not surprisingly, recent reviews/meta-analyses find these
‘‘acute’’ exposure studies to result in no significant beneficial or
impairing effects on cognitive performance [15,16]. Nonetheless,
several PET studies have reported that acute, single-exposure
EMF treatment can affect regional cerebral blood flow [17,18] and
increase brain glucose utilization [19], thus suggesting that even
acute high frequency EMF treatment can affect brain neuronal
activity.
Although results from acute, single EMF exposure studies are
insightful, they are most probably not indicative of the physiologic
and cognitive effects of long-term/daily EMF exposure (i.e. the
EMF exposure typical of cell phone users or the repeated EMF
treatments almost certainly required for any clinical EMF
applications). In this context, no controlled human studies have
investigated the ‘‘long-term’’ effects of high frequency EMF
treatment in normal or AD subjects over weeks, months, or years.
Nonetheless, two epidemiologic studies have provided initial
human evidence that years of high frequency EMF exposure are
associated with cognitive benefit. One of these studies found that
heavy cell phone use over several years resulted in better
performance of normal subjects on a word interference test [2],
while the other study reported that long-term cell phone users
(.10 years) had a 30–40% decreased risk of hospitalization due to
AD and vascular dementia [3].
The lack of controlled human studies investigating cognitive
effects of ‘‘long-term’’ EMF exposure/treatment has at least been
partially negated by our highly controlled EMF treatment studies
in AD Tg mice and littermate non-transgenic (NT) mice [4,5]. In
the first long-term, high frequency EMF treatment study
evaluating cognition in adult humans or animals [4], we reported
that treatment (at cell phone levels of 918 MHz/0.25–1.05 W/kg;
pulsed and modulated) over 7–9 months prevented or reversed
cognitive impairment in AD Tg mice bearing the APPsw
mutation. Even normal mice showed EMF-induced cognitive
enhancement in that initial study. For AD mice, the primary
mechanism of cognitive benefit appears to be a suppression of
brain Ab aggregation into neuritic plaques, presumably resulting
in greater Ab efflux from the brain [4]. Moreover, the cognitive
benefits of long-term EMF treatment to both AD mice and normal
mice occurs without any evidence of tissue abnormalities in either
the brain or peripheral tissues, without any evidence of increased
oxidative stress in the brain, and without any increase in DNA
damage to circulating blood cells. Thus, long-term EMF treatment
in mice appears safe in having no deleterious side effects across
multiple sensitive markers of brain/body function.
In a second study that involved AD Tg mice bearing the
APPsw+PS1 double mutation, we reported that daily EMF
treatment for one month enhances the impaired brain mitochon-
drial function of these AD mice, as well as the brain mitochondrial
function of normal mice [5]. These EMF-induced mitochondrial
enhancements occurred through ‘‘non-thermal’’ mechanisms
because brain temperatures were either stable or decreased during
and after daily high frequency EMF treatments. Since this EMF-
induced mitochondrial enhancement in AD mice was linked to
dramatic 5–10 fold elevations in soluble Ab within the same
mitochondria, EMF treatment disaggregated toxic Ab oligomers
therein, apparently resulting in very high monomeric Ab levels
(which are innocuous to mitochondrial function). Our mitochon-
drial function results in Dragicevic et al. [5] collectively suggest
that brain mitochondrial enhancement may be a primary
mechanism through which long-term EMF treatment provides
cognitive benefit to both AD mice and NT mice.
In a third study, we have most recently reported that two
months of daily EMF treatment enhances neuronal activity in the
entorhinal cortex of aged Alzheimer’s Tg mice and littermate NT
mice [20]. This EMF-induced enhancement of neuronal activity
was temporally linked to cognitive benefit in the same animals.
Based on these results, we have suggested that EMF treatment
could be a viable approach to counter the neuronal hypo-activity
that occurs very early in AD pathogenesis [20].
It is noteworthy that our prior EMF studies [4,5,20] identified
the first biologic mechanisms that could explain the EMF-induced
cognitive benefits, which we also reported in normal and
Alzheimer’s Tg mice (i.e., anti-Ab aggregation, mitochondrial
enhancement, and enhanced neuronal activity). The fact that our
long-term EMF treatment involves pulsed, modulated GSM signal
is important because a recent, comprehensive review concluded
that EMF-induction of biologic effects occurs primarily with
GSM-type modulation and a pulsed signal - not continuous wave
or UMTS fields [21].
Our initial behavioral study in AD Tg mice involved long-term
EMF treatment to young adult APPsw mice (from 2–7.5 months of
age), as well as to older APPsw adults (from 5–13.5 months of age)
[4]. Inasmuch as Ab pathology was not yet well established when
treatment began for these mice, the beneficial effects reported
were most relevant to human EMF treatment in pre-symptomat-
ic/prodromal AD or in mild cognitive impairment (MCI), the
prelude to AD. The present study extends our earlier findings by
evaluating the impact of long-term EMF treatment given to very
old 21–26 month-old APPsw and APPsw+PS1 mice, both of which
bear much heavier brain Ab burdens/Ab levels than the APPsw
mice in our initial work. In these aged mice with advanced Ab
pathology, we evaluated an array of behavioral, neuropathologic,
and physiologic measures to get a clearer understanding of how
long-term EMF treatment might impact the aged and heavily Ab-
burdened brain. We report a profound ability of long-term EMF
treatment to reverse brain Ab deposition, induce changes in
regional cerebral blood flow, and provide selected cognitive
benefits - all without induction of brain hyperthermia.
Results
Behavioral assessment during long-term EMF treatment
In Study I, behavioral testing of aged Tg and NT mice between
1 and 2 months into daily EMF treatment indicated no deleterious
effects of EMF treatment on sensorimotor function (Table 1). For
both Tg and NT mice, general activity/exploratory behavior was
unaffected by EMF treatment, as indexed by open field activity
and Y-maze choices made. As well, balance and agility abilities
were not impacted in either Tg or NT mice by EMF treatment, as
indexed by balance beam and string agility performance. In both
of these tasks, however, an overall effect of genotype was presence,
with Tg mice having poorer balance/agility compared to NT mice
irrespective of EMF treatment (p,0.002). Finally, visual acuity
testing in the visual cliff task at the end of behavioral testing (2
months into EMF treatment) indicated no deleterious effects of
EMF treatment on vision in either Tg or NT mice.
For cognitive-based tasks/measures, EMF effects were task
specific with benefits observed in the Y-maze task, but no effects in
either the circular platform or radial arm water maze (RAWM)
tasks. In the Y-maze alternation task of general mnemonic
function, both Tg and NT mice being given EMF treatment
showed near-significance increases in percent alternation com-
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no difference in performance of Tg and NT mice, these genotypic
groups were combined to determine if an overall EMF treatment
effect was present. Indeed, a significant increase in spontaneous
alternation percentage was evident irrespective of genotype
(Fig. 1A, right), indicating a beneficial effect of EMF treatment
on general mnemonic function. In the circular platform task of
spatial/reference memory, Tg mice were impaired vs. NT controls
during the final (2
nd block) of testing, irrespective of whether they
were receiving EMF treatment or not (Fig. 1B). Furthermore,
EMF treatment did not improve the poor performance (e.g, high
escape latencies) of both Tg and NT mice in this task.
For the RAWM task of working memory, all animals were
tested prior to the start of EMF treatment to establish baseline
performance levels and to determine if a transgenic effect was
present. Throughout pre-treatment RAWM testing, both Tg and
NT mice showed the high escape latencies typically seen during
the naı ¨ve first trial (T1), as exemplified by the last block of pre-
treatment testing (Fig. 2A). By contrast, Tg mice showed a severe
working memory impairment compared to NT mice at individual
test blocks and overall, as exemplified by their substantially higher
escape latencies during working memory Trial 5 (T5) for the last
block of pre-treatment testing (Fig. 2A). Following completion of
pre-treatment testing, Tg mice were divided into two sub-groups
balanced in RAWM performance (as were NT mice), with one
sub-group receiving EMF treatment and the other group not.
Ensuing RAWM testing at both 1 month and 1.5 months into
EMF treatment continued to show substantially impaired working
memory (T5) performance in Tg mice vs. NT controls, irrespective
of whether they were receiving EMF treatment or not (Figs. 2B,
C). The similar T5 working memory impairment of Tg+EMF
mice and Tg controls (evident during individual blocks and
overall) is exemplified by the last block of testing, as shown in
Figs. 2B and C.
Thus, EMF-induced cognitive benefits to very old AD and NT
mice were selective in enhancing general mnemonic function (Y-
maze alternation), but not impacting spatial reference learning/
memory (circular platform) or working memory (radial arm water
maze).
Table 1. Sensorimotor measures in NT and Tg mice given
long-term EMF treatment.
NT NT+EMF Tg Tg+EMF
Open Field (line crossings) 91621 115615 90628 122634
Y-maze (# of choices) 24642 2 612 6 652 4 63
Balance Beam (sec) 4.260.2 4.660.7 2.560.6 1.560.8
String Agility (score) 3.060.6 2.660.4 1.560.5 0.560.3
Visual Cliff (score) 2.0601 . 8 60.2 1.860.2 1.960.1
doi:10.1371/journal.pone.0035751.t001
Figure 1. Cognitive performance of non-transgenic (NT) and APPsw transgenic (Tg) mice in the Y-maze task of spontaneous
alternation (Fig. 1A) and the circular platform task of spatial/reference memory (Fig. 1B). (Fig. 1A) Both NT and Tg mice given EMF
treatment exhibited nearly significant increases in Y-maze percent alternation. For both genotypes combined, a significant increased in percent
alternation was evident in EMF-treated mice. *p,0.05 vs. control. (Fig. 1B) EMF treatment did not improve the poor performance of NT and Tg mice
in the circular platform task, although Tg mice were impaired even more than NT mice irrespective of treatment. **p,0.02 vs. NT.
doi:10.1371/journal.pone.0035751.g001
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Study I. Body and brain temperature measurements were
attained from aged animals in Study I before start of EMF
treatment (control) and at 1, 3, and 6 weeks into treatment (final
temperature measurements were unfortunately not taken at the 2-
month termination point of this study). Throughout the 6-week
study period, body and brain temperature recordings indicated
very stable temperature in control NT and control APPsw (Tg)
mice not being given EMF treatment (Fig. 3). By contrast, body
temperature for both EMF-treated NT and Tg mice was modestly
elevated by 0.5–0.9uC during ON periods compared to OFF
periods, from 1 week into EMF treatment onward through
treatment. For Tg mice, this increase in body temperature during
ON periods was evident even on the first day of EMF treatment.
During EMF OFF periods for both NT and Tg mice, body
temperature always came back down to their pre-treatment levels.
Since body temperature before start of EMF treatment was
identical for Tg mice (but not NT mice) to be given EMF or sham
treatment, temperature comparisons between these two groups
throughout the EMF treatment period also revealed that the
elevated body temperatures of Tg mice during ON periods always
came back down to sham control levels during OFF periods.
As indicated in Fig. 3, brain temperature in control NT and Tg
mice was usually 0.3–0.4uC lower than body temperature, which is
typically the case for rodents [22]. As with body temperatures,
brain temperature measurements in control NT and Tg mice (not
given EMF treatment) were very stable throughout the study. In
EMF-treated NT mice, elevations of 0.3–0.4uC in brain
temperature during ON periods were evident and significant by
3 weeks into treatment (Fig. 3). In EMF-treated Tg mice, however,
only trends for a slight increase in brain temperature were present
during ON periods. Thus, even with peripheral increases in
temperature during ON periods, brain temperature remained
stable or was only elevated minimally through 6 weeks of EMF
exposure. Following any brain temperature elevations during ON
periods, brain temperature always returned to pre-treatment levels
during OFF periods.
Study II. For the aged APPsw+PS1 (Tg) mice in Study II,
body and brain temperature measurements were taken before the
start of EMF treatment, as well as at 5 and 12 days into treatment
(Fig. 4). Though still modest, the difference between body and
brain temperature measurements for control APPsw+PS1 mice
throughout this study was larger (0.7–0.9uC) than for the body/
brain temperature differences of APPsw mice throughout Study I.
Despite receiving the same daily EMF exposure as APPsw mice in
Study I, APPsw+PS1 mice in this study showed no significant
increase in body or brain temperature during ON periods at 5 and
12 days into EMF treatment. For all time points evaluated, there
were no differences between EMF-treated and control Tg mice in
either body or brain temperature.
Cerebral blood flow measurements during long-term and
sub-chronic EMF treatment
Laser Doppler measurements of regional cerebral blood flow
(rCBF) in cerebral cortex were performed at 2 months into EMF
treatment for Study I and at 12 days into EMF treatment for Study
II. In Study I, control NT and Tg mice (not being given EMF
treatment) had very consistent rCBF readings between their sham
ON and OFF periods (Fig. 5A). Although NT+EMF mice
exhibited no change in rCBF between ON and OFF periods,
Tg mice showed a significant 13% decrease in rCBF during the
ON period vs. OFF period (Fig. 5A). The decreased rCBF present
in Tg mice during the ON period was even greater (Q25%) in
relation to rCBF in control Tg mice during their sham ON period.
Visual inspect of the data in Fig. 5A revealed rCBF measurements
during both OFF and ON periods to be lower in EMF-treated
mice compared to control (sham-treated) mice irrespective of
genotype. This, in addition to no genotypic differences in rCBF
being present for EMF-treated or control mice, warranted
combination of individual animal data from both genotypes to
determine the main effect of EMF during OFF and ON periods
(Fig. 5B). A significant decrease in rCBF was present not only
during ON periods for EMF vs. control mice, but also present
during OFF periods as well. Thus, EMF effects on rCBF were
present not only during ON periods, but also during OFF periods,
at 2 months into EMF treatment.
rCBF measurements in Study II only involved Tg mice and at a
shorter 12-days into the same daily EMF exposure. As shown in
Fig. 5C, control Tg mice had stable and similar rCBF
Figure 2. Working memory in the radial arm water maze (RAWM) task pre-treatment, 1 month, and 1.5 months into EMF treatment
for the naı ¨ve first trial (T1) and working memory trial (T5) of APPsw transgenic (Tg) and non-transgenic (NT) mice. (Fig. 2A) Pre-
treatment RAWM testing revealed Tg mice to be impaired vs. NT mice during working memory Trial 5 on the last block of testing. *p,0.002 vs. NT;
(Fig. 2B) and (Fig. 2C). At both 1 month and 1.5 months into EMF treatment, Tg mice continued to be impaired in working memory (T5) performance
on the last block of testing, irrespective of whether they had been receiving EMF treatment or not. *p,0.01 or higher level of significance vs. NT.
doi:10.1371/journal.pone.0035751.g002
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nearly significant (p=0.10) reduction in rCBF (Q19%) was
present in EMF-treated Tg mice during their ON period vs. OFF
period at 12 days into EMF exposure. Supportive that a true
EMF-induced decrease in rCBF had indeed occurred, 4 out of five
Tg+EMF mice had decreases of 7–46% in rCBF during the ON
period compared to the OFF period. The significantly higher
rCBF present in EMF-treated mice vs. control Tg mice during the
OFF period was due to several EMF-treated mice with high rCBF
readings during both OFF and ON periods.
Ab immunohistochemistry
After two months of EMF treatment, the very old (23–28
months old) APPsw and NT mice in Study I were euthanized and
their brains processed for quantitative analysis of Ab deposition.
As expected, NT mice exhibited no human Ab immunostaining in
their brains irrespective of treatment. Very old Tg controls (Tg),
however, had extremely high levels of Ab deposition in both their
hippocampus and entorhinal cortex, bearing Ab burdens of 11–
12% in these two brain areas (Fig. 6B). In sharp contrast, Tg mice
that had received two months of EMF treatment exhibited
substantial decreases in Ab burden within both hippocampus
(Q30%) and entorhinal cortex (Q24%) compared to Tg controls
(Fig. 6B). Thus, EMF treatment reversed pre-existing Ab
Figure 3. Body and brain temperature measurements for non-transgenic (NT) and APPsw transgenic (Tg) mice recorded prior to the
start of EMF treatment (control), and at 1 Day, 1 week, 3 weeks, and 6 weeks into EMF treatment. Control NT and Tg mice (no EMF
exposure) maintained stable body and brain temperatures throughout the 6 week recording period. By contrast, both NT and Tg mice being treated
with EMF experienced small, but significant increases in body temperature during ON periods by 1 week into treatment and time points thereafter.
Although brain temperature of EMF-treated Tg mice remained stable during ON periods through the 6 week recording period, EMF-treated NT
exhibited small (but significant) increases in brain temperature during ON periods at 3 and 6 weeks into EMF treatment. *p,0.05 or higher level of
significance for OFF vs. ON recordings (via paired t-test) at that time point.
#p,0.02 vs. NT control on that day.
doi:10.1371/journal.pone.0035751.g003
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photomicrographs of typical Ab immunostained-plaques from
23–28 months old Tg and Tg+EMF mice, underscoring the
substantial reduction in Ab deposition present in brains of very old
Tg mice given a two-month period of daily EMF treatment.
Analysis of plasma samples taken at euthanasia revealed no effects
of EMF treatment on plasma Ab1–40 (46206442 pg/ml for Tg
vs. 48856920 pg/ml for Tg+EMF; p=0.78) or Ab1–42
(14526120 pg/ml for Tg vs. 11756251 pg/ml; p=0.30).
Discussion
We have previously reported that long-term (.6 months) EMF
exposure at cell phone level frequencies and SAR levels can
protect against or reverse cognitive impairment in Alzheimer’s Tg
mice, while even having cognitive benefit to normal mice [4].
Moreover, we previously provided the first mechanistic insight into
long-term EMF treatment by reporting the ability of such
treatment to suppress brain Ab aggregation/deposition in AD
mice, while enhancing brain mitochondrial function and neuronal
activity in both Tg and normal mice [4,5,20]. The present study
extends the above works by administering long-term (2 months) of
daily EMF treatment to very old Alzheimer’s Tg mice and
showing that such treatment can reverse their very advanced brain
Ab aggregation/deposition while providing selected cognitive
benefit to both Tg and normal mice. Moreover, these neuropath-
ologic and cognitive benefits occurred without appreciable
increases in brain temperature, indicating involvement of non-
thermal brain mechanisms (i.e., Ab anti-aggregation, mitochon-
drial enhancement, neuronal activity). Finally, the present study is
the first to determine the effects of long-term EMF exposure on
rCBF, and in the same animals evaluated for cognitive,
neuropathologic, and body/brain temperature endpoints. Our
finding of an EMF-induced decrease in cortical blood flow raises
several interesting mechanisms of action that merit consideration.
Cognitive and Ab deposition effects of EMF treatment
Two months of cell phone level EMF treatment (e.g., GSM,
918 MHz, 0.25–1.05 W/kg, pulsed and modulated) improved the
cognitive performance of very old (23–27 month old) Tg and NT
mice combined in the Y-maze task of spontaneous alternation.
This task evaluates general mnemonic function and is not
associated with brain Ab levels/deposition [23]. Thus, generalized
mechanisms irrespective of genotype, such as the brain mitochon-
drial enhancement present by one month into EMF treatment [5],
are most likely involved. The present Y-maze results are consistent
with our initial study [4] wherein we found Y-maze spontaneous
alternation to be significantly increased in NT mice given long-
Figure 4. Body and brain temperature measurements for APPsw+PS1 transgenic (Tg) mice recorded prior to the start of EMF
treatment (control), as well as at 5 days and 12 days into EMF treatment. For both control and treatment time points, there were no
differences between EMF-treated and control Tg mice for either body or brain temperatures. No significant differences in OFF vs. ON temperatures
(via paired t-test) were evident in EMF-treated Tg mice.
doi:10.1371/journal.pone.0035751.g004
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not able to reverse the cognitive impairment in two tasks wherein
performance is linked to brain Ab levels/deposition - the circular
platform task of spatial/reference memory and RAWM task of
working memory [23]. The RAWM task, in particular, is very
sensitive to brain Ab deposition, with poorer working memory
performance highly correlated with extent of Ab deposition in
both hippocampus and cortex.
Although the very old Tg mice of this study had extraordinarily
high brain Ab burdens (11–12%) that were substantially reduced
(Q24–30%) by EMF treatment, this large quantitative reduction
in Ab deposition was apparently not sufficient for cognitive benefit
to become manifest in tasks linked to brain Ab levels/deposition. A
longer EMF treatment period or more effective EMF parameters
is probably needed to attain widespread behavioral benefit in these
very old Tg mice. In our initial study [4], 6–7 months of daily
EMF treatment was required to manifest widespread cognitive
benefit in younger Tg mice bearing only around 2% brain Ab
burdens. Parenthetically, animals in the present study were given
double the daily EMF exposure (two 2-hour periods) compared to
our initial study (two 1-hour periods). For both studies, a more
effective removal of Ab from the brain through greater EMF-
induced Ab disaggregation and ensuing greater removal of
resultant soluble Ab from the brain into the blood would appear
to be key to realization of earlier cognitive benefits.
It is important to underscore that an absolute reduction in brain
‘‘soluble’’ Ab is not required to get EMF-induced cognitive
benefits, as we have repeatedly demonstrated for various AD
therapeutics including EMF treatment [4,24,25]. This is because
the disaggregating action of EMF treatment on brain Ab (from
insoluble to soluble forms) appears to shift most soluble Ab from
the cognitive-impairing ‘‘oligomeric’’ form to smaller (innocuous)
dimeric/monomeric forms. That is the probable reason why we
observed brain mitochondrial enhancement in aged Tg mice given
Figure 5. Regional cerebral blood flow (rCBF) in cerebral cortex of NT and Tg mice in Studies I and II obtained by Laser Doppler
measurements at the end of their 2 month and 12-day EMF treatment periods, respectively. (Fig. 5A) At 2 months into EMF treatment for
Study I, APPsw transgenic (Tg) mice exhibited a significant 13% decrease in rCBF during ON vs. OFF periods. During ON periods, an even greater
reduction in rCBF for EMF-treated Tg mice was evident when compared to Tg controls. *p,0.05 vs. OFF period by paired t-test. (Fig. 5B) Evaluation of
rCBF results from Study I irrespective of genotype revealed that EMF-treated mice had significantly reduced rCBF during both ON and OFF periods.
wp,0.05 vs. No EMF;
wwp,0.0001 vs. No EMF. (Fig. 5C) At 12 days into EMF treatment for Study II’s APPsw+PS1 (Tg) mice, a near-significant rCBF
reduction of 19% was present in EMF-treated Tg mice during ON vs. OFF periods.
{p=0.10 for ON vs. OFF (paired t-test);
#p,0.05 vs. Tg control
during OFF period.
doi:10.1371/journal.pone.0035751.g005
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having 5–106higher soluble Ab in their brain mitochondria (i.e.,
most of this soluble Ab was in innocuous monomeric/dimeric
forms) [5]. Such enhanced levels of monomeric/soluble Ab are
also consistent with the lack of EMF-induced reductions in plasma
Ab levels observed in the present study, as well as in our earlier
EMF study [4].
Prior to our recent study showing cognitive efficacy of ‘‘cell
phone-level’’ EMF exposure administered daily for .6 months to
Tg and normal mice [4], animal studies investigating cognitive
effects of cell phone level EMF exposure involved ‘‘normal’’ mice/
rats receiving daily ‘‘head-only’’ [26–28] or ‘‘full body’’ [29] EMF
exposure for a relatively short 4–14 days. No cognitive benefits
were reported in those studies, nor did longer 2- or 6-month
periods of daily head-only EMF exposure impact cognitive
performance in normal rats [28]. However, a 5-week period of
cell phone level EMF exposure to immature (3 weeks old) rats did
improve their rate of learning in the Morris water maze task [30].
It is important to note that future rodent studies emphasize ‘‘head-
only’’ EMF exposure over many months and utilize a compre-
Figure 6. Brain Ab deposition in APPsw transgenic (Tg) mice at 2 months after EMF treatment (Study I). (Fig. 6A) Photomicrographs
showing the visually evident decrease in Ab deposition in both hippocampus (H) and entorhinal cortex (EC) of EMF-treated mice compared to
control/sham mice. Micrometer bar=50 mm. (Fig. 6B) Quantification of percent Ab burdens from EMF-treated and control/sham Tg mice. Highly
significant reductions in Ab deposition/aggregation were present in both hippocampus (Q30%) and entorhinal cortex (Q24%) of EMF-treated mice.
*p,0.005 vs. Tg controls for that brain area.
doi:10.1371/journal.pone.0035751.g006
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measure/task).
In humans, all cell phone level EMF studies investigating
cognitive function have been unilateral and involved either single
EMF exposure [15,16] or daily EMF exposure for 6–27 days
[13,14], with no cognitive effects being reported in either case.
However, one study did report that heavy cell phone users
evaluated over a 2-year period performed better in a word
interference test [2]. Clearly, there is a critical need for long-term,
well-controlled EMF studies in humans to evaluate cognitive
effects in both normal and cognitive-impaired individuals.
Body/brain temperature and cerebral blood flow effects
of EMF treatment
Before our own recent work [4,5] and the present study, only
one prior animal study investigated the effects of EMF exposure on
body/brain temperature and/or cerebral blood flow [31]. That
study, involving a single head-only GSM exposure for 18 minutes
to anesthetized rats, was at very high frequency (2000 MHz) and
very high SAR levels (10–263 W/kg). This acute EMF exposure
increased brain temperature in a dose-dependent fashion (by 1–
12uC), and increased cortical cerebral blood flow (by 30–70%). In
humans, no studies investigating EMF effects on brain tempera-
ture have apparently been done in living individuals, and EMF
effects on cerebral blood flow have only involved a single,
unilateral EMF exposure, with inconsistent results [16]. Thus, for
both animals and humans, there had previously been no
investigations into long-term EMF effects on brain temperature
or cerebral blood flow.
Regarding temperature, our recent studies [4,5] have investi-
gated both acute and long-term body/brain temperature effects of
EMF treatment (i.e., GSM, pulse/modulated at 918 MHz and
0.25–1.05 W/kg), with the following findings: 1) a single day of
EMF treatment has no effect on body or brain temperature of
either AD Tg or normal mice during ON periods; 2) At 8–9
months into daily EMF treatment, body temperature of both Tg
and NT mice is elevated by approximately 1uC during ON
periods; and 3) At 1 month into daily EMF treatment, body
temperature of aged Tg and NT mice is elevated by around 1uC
during ON periods while brain temperatures are either stable (NT
mice) or decreased (Tg mice) during ON periods. For both long-
term EMF studies in 2) and 3), body temperature always returned
back down to normal levels during OFF periods.
The present work extends our aforementioned initial findings by
performing two separate temperature-monitoring studies in order
to evaluated sub-chronic (12 days) and long-term (6 weeks) effects
of daily EMF treatment on both body and brain temperature
measurements in very old AD mice and normal mice. During
multiple temperature measurements taken over a 6-week period in
very old mice that had been behaviorally tested, small (but
significant) increases of around 0.5uC in body temperature were
evident in both Tg and normal mice. This small increase of ,1uC
in body temperature during ON periods of long-term EMF
treatment is very consistent with that seen in our prior studies
[4,5]. Despite these small, but significant increases in body
temperature during ON periods, brain temperature for Tg and
normal mice remained stable or was only elevated 0.3–0.4uC
through 6 weeks of exposure - far below what would be needed to
incur brain/physiologic damage [32]. Thus, the EMF-induced
cognitive benefits in mice that we have reported both in our prior
report [4] and presently are apparently due to non-thermal brain
mechanisms - several of which we have already identified (see last
section).
In the sub-chronic (12-day) EMF treatment study, very old
APPsw+PS1 (Tg) mice exhibited no change in body or brain
temperature during ON periods at both 5 days and 12 days into
EMF treatment. This is somewhat in contrast to the long-term
study, wherein a significant increase in body temperature during
ON periods was already present at 1 week into EMF treatment,
although no change in brain temperature occurred (same as in
sub-chronic study). The only difference between the two studies,
other than temperature recording points, was that double Tg
(APPsw+PS1) mice were used in the sub-chronic study, which
would have even greater brain Ab burdens than the APPsw mice
used in the long-term study.
At 2 months into daily EMF treatment in the long-term study,
Tg mice (but not normal mice) exhibited a significant 13%
decrease in rCBF during ON vs. OFF periods. This EMF-induced
reduction in rCBF was even greater (Q25%) compared to control
Tg mice during sham ON periods. The difference between Tg and
NT mice is brain production and aggregation/deposition of Ab in
Tg mice. Earlier studies have provided evidence that EMF
treatment increases neuronal activity [16,19,21,33,34]. As men-
tioned previously, our very recent findings show that long-term
EMF treatment does indeed increase neuronal activity in Tg and
NT mice, irrespective of genotype [20]. Since intraneuronal Ab is
synaptically released in greater amounts during increased neuronal
activity [35], there is presumably greater efflux of this soluble/
monomeric Ab out of the brain and into the blood during EMF
exposure. Inasmuch as vascular Ab is a well-known constrictor of
smooth muscle in resistance vessels (e.g., arterioles), we believe that
this enhanced presence of cerebrovascular Ab due to EMF
exposure induces cerebral vasoconstriction and the resulting
decreases in rCBF that were observed in Tg mice.
Also in the long-term (2 months) study, rCBF was reduced even
during OFF periods in both Tg and normal mice being given EMF
treatment. Indeed, when both genotypes were combined to
investigate main effects of EMF treatment, rCBF was significantly
decreased during both ON (Q23%) and OFF (Q16%) periods.
Clearly, some non-specific EMF mechanism is reducing rCBF
during OFF periods in both Tg and NT mice. For example, this
may be a continuing auto-regulatory response to limit brain
heating due to the slight body hyperthermia present during ON
periods. Along this line, body hyperthermia (such as that induced
by exercise) has been shown to decrease cerebral blood flow in
humans by 18% [36,37]. The reductions in rCBF presently
observed during both ON and OFF periods of long-term EMF
treatment in Tg and NT mice are consistent with several human
PET studies reporting that rCBF is reduced during single exposure
EMF treatment [18,38].
Similar to rCBF results from the long-term EMF study,
evaluation of rCBF at 12 days into EMF treatment for
APPsw+PS1 (Tg) mice in the sub-chronic study revealed a near
significant 19% decrease in rCBF during ON periods. Indeed, 4 of
5 Tg-treated mice exhibited rCBF decreases of 7–46%. Since
there was no increase in body temperature during ON periods,
there was no need for themoregulatory mechanisms to limit CBF
to the brain. However, it is likely that during ON periods, elevated
vascular Ab caused a modest vasoconstriction in the brain and the
ensuing decrease in CBF that was observed.
Mechanisms of long-term EMF action and evidence for
EMF safety
Results from the present study, in concert with those from our
prior three studies [4,5,20], are beginning to provide critical
mechanistic insight into the ability of long-term, high frequency
EMF exposure to benefit cognitive function in normal and AD
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mechanisms, which are relevant to human long-term EMF
exposure as well. Although this summary diagram is the result of
long-term studies involving GMS-modulated and pulsed EMF
treatment at specific parameters (918 MHz, 0.25–1.05 W/kg),
different combinations of frequency/SAR levels will likely provide
more robust mechanistic actions within this circuit and expand it,
resulting in greater or more rapid cognitive benefit.
As depicted in Fig. 7 for AD mice, high frequency EMF
treatment would appear to exert two complementary actions that
ultimately result in enhanced Ab removal/efflux from the brain: 1)
prevention and reversal of brain Ab aggregation/deposition [4],
and 2) increased neuronal/EEG activity [16,20,19–21,33,34].
EMF treatment’s suppression of extracellular and intracellular Ab
aggregation, combined with enhanced synaptic release of intra-
neuronal Ab during increased neuronal activity [35], result in
soluble monomergic forms of free Ab in the brain parenchyma -
Ab forms that can be readily transported across the blood-brain
barrier [39] and into the blood for eventual degradation. As
previously mentioned, soluble/monomeric Ab is a powerful
vasoconstrictor [40,41], which is probably key to the substantial
decrease in rCBF present during EMF ON periods in Tg mice.
Since Ab is not a factor for EMF effects in normal mice, normal
mice incur a less robust, generalized decrease in CBF through
some as yet unidentified mechanism (e.g., compensatory to EMF-
induced increases in body temperature). Similarly, long-term EMF
treatment to Tg mice induces large enhancements in brain
mitochondrial function due to disaggregation of mitochondrial-
impairing oligomeric Ab in neurons, with a lesser enhancement
present in normal mice due to an as yet unidentified mechanism
[5].
All of the aforementioned EMF mechanisms occur in mice with
only a slight (or no) increase in brain temperature [5] and no
increase in brain oxidative stress/damage [4]. Indeed, examina-
tion of both peripheral and brain tissues from animals given daily
EMF treatment for over 8 months has revealed no tissue
abnormalities [4], including no increase in DNA damage to blood
cells from these same animals [Cao et al., unpublished
observations]. The lack of deleterious brain and peripheral effects
in such long-term EMF studies, in combination with recent
epidemiologic human studies also reporting no consistent evidence
for EMF-induced health problems [10–12], underscores the
mounting evidence that high frequency EMF treatment over long
periods of time, could be a safe and novel disease-modifying
therapeutic against AD.
Materials and Methods
Ethics statement
All animal procedures were performed in AAALAC-certified
facilities under protocol #R3258, approved by the University of
South Florida Institutional Animal Care and Use Committee.
Animals
For both studies of this work, a total of 41 aged mice derived
from the Florida Alzheimer’s Disease Research Center’s colony
were included. Each mouse had a mixed background of 56.25%
C57, 12.5% B6, 18.75% SJL, and 12.5% Swiss-Webster. All mice
were derived from a cross between heterozygous mice carrying the
mutant APPK670N, M671L gene (APPsw) with heterozygous PS1
(Tg line 6.2) mice, which provided offspring consisting of
APPsw+PS1, APPsw, PS1, and NT genotypes. After weaning
and genotyping of these F10 and F11 generation offspring, APPsw
Figure 7. Summary diagram depicting both confirmed and proposed mechanisms of long-term EMF action in normal mice and
Alzheimer’s transgenic (Tg) mice. Long-term EMF actions that we have confirmed include prevention/reversal of brain Ab aggregation, brain
mitochondrial enhancement, and reduced cortical cerebral blood flow (CBF). These long-term EMF actions occur through slight/no increase in brain
temperature and without increasing brain oxidative stress/damage.
doi:10.1371/journal.pone.0035751.g007
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(Study I), while APPsw+PS1 mice were selected for a follow-up,
shorter duration temperature/cerebral blood flow-monitoring
study (Study II) - aged APPsw were not available for the ensuing
Study II. All mice were housed individually after genotyping,
maintained on a 12-hour dark and 12-hour light cycle with ad
libitum access to rodent chow and water.
Study I: Two-month EMF Treatment Study
At 21–26 months of age, APPsw Tg mice (n=17) and NT
littermates (n=10) were first evaluated in RAWM task of working
memory (see Behavioral testing protocols) to establish baseline
cognitive performance for both genotypes prior to EMF treatment.
Based on pretreatment performance in the RAWM task, Tg and
NT groups were each divided into two performance-balanced sub-
groups as follows: Tg controls (n=8), Tg+EMF (n=9), NT
controls (n=5), and NT+EMF (n=5). Tg and NT mice to be
exposed to EMFs had their cages placed within a large Faraday
cage, which contained an EMF generator antenna that provided
two 2-hour periods of EMF treatment per day (see EMF treatment
protocol). At 22–27 months of age (one month into EMF
treatment), all mice were started on a one-month series of
behavioral tasks. EMF treatment was continued during the one-
month behavioral testing period, with all testing performed during
‘‘OFF’’ periods in between the two daily EMF treatments. Body
and brain temperature measurements were performed just prior to
initiation of EMF treatment and at 1, 3, and 6 weeks into EMF
treatment (see Body/brain temperature determinations). Doppler
recordings of rCBF were taken at 2 months in EMF treatment (see
rCBF determinations). On the day following rCBF measurements,
animals were euthanized at 23–28 months of age, during which a
blood sample was taken and brains were perfused with isotonic
phosphate-buffered saline (PBS). The caudal brain was then
paraffin-embedded and processed for Ab immunohistochemical
staining, while the remaining forebrain was sagitally bisected and
dissected into hippocampus and cortical areas that were quick-
frozen for neurochemical analyses. Plasma was analyzed for both
Ab1–40 and Ab1–42.
Study II: 12-day EMF Treatment Study
At 22 months of age, 11 APPsw+PS1 Tg mice were divided into
two groups of 5–6 mice each. One group was placed into the
faraday cage for two daily EMF exposures exactly as for mice in
the 2-month EMF Treatment Study (see EMF treatment protocol).
The other group served as EMF controls, housed in a completely
separate room with an identical environment without EMF
treatment. Body and brain temperature recordings were taken
from all mice just prior to onset of the first EMF treatment, as well
as on the 5
th day and 12
th day into EMF treatment. Concurrent
with temperature recording on Day 12, cerebral blood flow
measurements were also taken.
EMF treatment protocol
Tg and NT mice given EMF treatment were individually
housed in cages within a large Faraday cage, which also housed
the antenna of an EMF generator providing two 2-hour periods of
electromagnetic waves per day (early morning and late afternoon).
Each EMF exposure was at 918 MHz frequency, involved
modulation with Gaussian minimal-shift keying (GMSK) signal,
and was pulsed/non-continuous with carrier bursts repeated every
4.6 ms, giving a pulse repetition rate of 217 Hz. The electrical
field strength varied between 17 and 35 V/m. This resulted in
calculated SAR levels that varied between 0.25 and 1.05 W/kg.
Calculated SAR values have been shown to correspond closely
with measured SAR values [42]. SAR was calculated from the
below equation, with s (0.88 sec/m) and r (1030 kg/m
3) values
attained from Nightingale et al. [43]:
SAR~sE2=r
s=mean electrical conductivity of mouse brain tissue.
r=mass density of mouse brain.
E=electrical field strength.
For the 2-month and 12-day periods of EMF treatment given to
mice in Study’s I and II, respectively, cages of individually-housed
mice were maintained within the Faraday cage (1.261.261.2 m
3)
and arranged in a circular pattern. Each cage was approximately
26 cm from a centrally located EMF-emitting antenna. The
antenna was connected to a Hewlett–Packard ESG D4000A
digital signal generator (Houston, TX, USA) set to automatically
provide two 2-hour exposures per day. With a 12-hour light ON/
OFF cycle, the 2-hour daily exposures occurred in early morning
and late afternoon of the lights on period. Sham-treated control
Tg and NT mice were located in a completely separate room, with
identical room temperature as in the EMF exposure room and
with animals individually housed in cages that were arranged in
the same circular pattern.
Behavioral Testing Protocols
Prior to EMF treatment, all mice in Study I were behaviorally
tested for 10 days in RAWM task of working memory to determine
baseline cognitive performance in this task. Daily EMF treatment
was then started, with behavioral testing initiated at one month
into EMF treatment and occurring between early morning and
late afternoon EMF treatments. One-day tasks of sensorimotor
function were initially carried out (open field activity, balance
beam, string agility), followed by a one-day Y-maze task
(locomotor activity, spontaneous alternation), then RAWM Test
I (4 days), circular platform performance (4 days), RAWM Test II
(4 days), then finally the visual cliff test of visual acuity (1 day).
Although the methodologies for all of these tasks have been
previous described and are well established [44–46], a brief
description of each task is provided below:
Open field activity. Open field activity was used to measure
exploratory behavior and general activity. Mice were individually
placed into an open black box 81681 cm with 28.5-cm high walls.
This area was divided by white lines into 16 squares measuring
20620 cm. Lines crossed by each mouse over a 5-minute period
were counted.
Balance beam. Balance beam was used to measure balance
and general motor function. The mice were placed on a 1.1-cm
wide beam, suspended above a padded surface by two identical
columns. Attached at each end of the beam was an escape
platform. Mice were placed on the beam in a perpendicular
orientation and were monitored for a maximum of 60 secs. The
time spent by each mouse on the beam before falling or reaching
one of the platforms was recorded for each of three successive
trials. If a mouse reached one of the escape platforms, a time of
60 secs was assigned for that trial. The average of all three trials
was utilized.
String agility. String agility was used to assess forepaw grip
capacity and agility. Mice were placed in the center of a taut
cotton string suspended above a padded surface between the same
two columns as in the balance beam task. Mice were allowed to
grip the string with only their forepaws and then released for a
maximum of 60 secs. A rating system, ranging between 0 and 5,
was employed to assess string agility for a single 60-sec trial.
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alternation was used to measure general activity and basic
mnemonic function. Mice were allowed 5 minute to explore a
black Y-maze with three arms. The number and sequence of arm
choices were recorded. General activity was measured as the total
number of arm entries, while basic mnemonic function was
measured as a percentage of spontaneous alternation (the ratio of
arm choices different from the previous two choices divided by the
total number of entries).
Circular platform. Circular platform was used to measure
spatial/reference learning and memory. Mice were placed on a
69-cm circular platform with 16 equally spaced holes on the
periphery of the platform. Underneath only one of the 16 holes
was a box filled with bedding to allow the mouse to escape from
aversive stimuli (e.g. two 150-W flood lamps hung 76 cm above
the platform and one high-speed fan 15 cm above the platform).
Each mouse was administered one 5-minute trial per day to
explore the area. For the single trial administered on each of four
test days, mice were placed in the center of the platform facing
away from their escape hole (which differed for each mouse).
Escape latency was measured (maximum of 300 secs) each day.
Data was statistically analyzed in two 2-day blocks.
RAWA. RAWA task of spatial working memory involved use
of an aluminum insert, placed into a 100 cm circular pool to
create 6 radially distributed swim arms emanating from a central
circular swim area. An assortment of 2-D and 3-D visual cues
surrounded the pool. The latency and number of errors prior to
locating which one of the 6 swim arms contained a submerged
escape platform (9 cm diameter) was determined for 5 trials/day
over 10 days of pre-treatment testing. There was a 30-minute time
delay between the 4
th trial and the 5
th trial (T5; memory retention
trial). The platform location was changed daily to a different arm,
with different start arms for each of the 5 trials semi-randomly
selected from the remaining 5 swim arms. During each trial (60-sec
maximum), the mouse was returned to that trial’s start arm upon
swimming into an incorrect arm and the number of seconds
required to locate the submerged platform was recorded. If the
mouse did not find the platform within a 60-sec trial, it was guided
to the platform for the 30-sec stay. The latency and number of
errors during Trial 1 (T1) are chance performance since the
animal does not know where the submerged platform is for the first
trial of any given day. Latency and errors during the last trial
(Trial 5; T5) of any given day are considered indices of working
memory and are temporally similar to the standard registration/
recall testing of specific items used clinically in evaluating AD
patients. Data for T1 and T5 were statistically analyzed in two-day
blocks, as well as overall, for the 10-day of pretreatment RAWM
testing, the 4-day of RAWM Test I, and the 4-day of RAWM Test
II. Because the final block of testing is most representative of true
working memory potential in this task, results from the last 2-day
block of testing are presented for all three RAWM test periods.
Visual Cliff. Visual Cliff was utilized on the last day of
behavioral testing to evaluate vision/depth perception. A wooden
box has two horizontal surfaces, both of which have the same bold
pattern, but one surface of which is 10–12 inches below the other.
A sheet of clear Plexiglass is placed across the entire horizontal
surface, providing the visual appearance of a cliff. An animal with
poor vision/depth perception cannot detect the ‘‘cliff’’ and will
move without hesitation across the cliff, resulting in a score of ‘‘1’’.
An animal with good vision will pause/hesitate at the cliff before
crossing it and is scored a ‘‘2’’.
Body/brain temperature determinations
For body/brain temperature determinations of mice in both
Studies I and II, body temperature was taken via rectal probe and
brain temperature via temporalis muscle probe. Prior studies have
demonstrated that temporalis muscle temperature very accurately
reflects brain temperature in rodents [47,48]. Temperature
determinations during EMF treatment (ON periods) were taken
near the end of the morning EMF treatment, while temperature
determinations during OFF periods were in early afternoon (mid-
way between the two daily EMF treatments). Each measurement
only took a couple of minutes for each mouse.
rCBF determinations
In cerebral cortex, rCBF measurements during the ON period
were taken near the end of either the morning EMF treatment
session (Study I) or the afternoon treatment session (Study II).
rCBF measurements during the OFF period were taken in early
afternoon, mid-way between both EMF treatment sessions. For
each measurement, anesthetized (equithesin 300 mg/kg i.p.)
animals underwent rCBF measurement using laser Doppler
flowmetry (PF-5010, Periflux system, Ja ¨rfa ¨lla, Sweden) with
relative flow values expressed as perfusion units [49,50]. All rCBF
measurements were conducted with the animal fixed in a Kopf
stereotaxic apparatus, with the probe placed at the level of the
dura directly above a small skull opening. Using a micromanip-
ulator, two probes (probe 411, 0.45 mm in diameter) were
positioned to cortical coordinates of 1.3 mm posterior to the
bregma and 2.8 mm to each side of midline on the intact skull,
being careful to avoid pial vessels after reflection of the skin
overlying the calvarium. Because mouse skull and subarachnoid
space are very thin, transcranial measurements of rCBF are
consistent with craniectomy measurements [51]. The rCBF of
both hemispheres were continuously measured for 15 minutes and
averaged for each determination. All rCBF data was continuously
stored in a computer and analyzed using the Perimed data
acquisition and analysis system.
Ab immunohistochemistry and image analysis
At the level of the posterior hippocampus (bregma 22.92 mm
to 23.64 mm), five 5 mm sections (150 mm apart) were taken from
each mouse brain using a sliding microtome (REM-710, Yamato
Kohki Industrial, Asaka, Saitama, Japan). Immunohistochemical
staining was performed following the manufacturer’s protocol
using aVectastainABC Elite kit (Vector Laboratories, Burlingame,
CA) coupled with the diaminobenzidine reaction, except that the
biothinylated secondary antibody step was omitted. Used as the
primary antibody was a biothinylated human Ab monoclonal
antibody (clone 4G8; 1:200, Covance Research Products, Emery-
ville, CA). Brain sections were treated with 70% formic acid prior
to the pre-blocking step. 0.1 M PBS (pH 7.4) or normal mouse
serum (isotype control) was used instead of primary antibody or
ABC reagent as a negative control. Quantitative image analysis
was done based on previously validated method [52]. Images were
acquired using an Olympus BX60 microscope with an attached
digital camera system (DP-70, Olympus, Tokyo, Japan), and the
digital image was routed into a Windows PC for quantitative
analysis using SimplePCI software (Hamamatsu Photonics,
Hamamatsu, Shizuoka, Japan). Images of five 5-mm sections
(150 mm apart) through both anatomic regions of interest
(hippocampus and entorhinal cortex) were captured from each
animal, and a threshold optical density was obtained that
discriminated staining from background. Each region of interest
was manually edited to eliminate artifacts, with Ab burden data
reported as percentage of immune-labeled area captured (positive
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was done by a single examiner blinded to sample identities.
Plasma Ab levels
Ab1–40 and 1–42 levels were determined from plasma samples
by using ELISA kits (KHB3482 for 40, KHB3442 for 42,
Invitrogen, CA). Standard and samples were mixed with detection
antibody and loaded on the antibody pre-coated plate as the
designated wells. HRP-conjugated antibody was added after wash,
and substrates were added for colorimetric reaction, which was
then stopped with sulfuric acid. Optical density was obtained and
concentrations were calculated according a standard curve.
Statistical Analysis
Data analysis of physiologic and neurohistologic measurements,
as well as all one-day behavioral measures, were performed using
ANOVA followed by Fisher’s LSD post hoc test. For the multiple-
day behavioral tasks (RAWM and circular platform), initial
ANOVA analysis of 2-day blocks and overall were followed by
analysis of post hoc pair-by-pair differences between groups via the
Fisher LSD test. For temperature and blood flow measurements
within the same animal, paired t-tests were employed. All data are
presented as mean 6 SEM, with significant group differences
being designated by p,0.05 or higher level of significance.
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